RudaCure (CEO Yongho Kim), a company specializing in developing treatments for sensory disorders, was selected as an Incheon Outstanding Company (Promising Enterprise) at the '2025 Incheon SME Awards and Outstanding Enterprise Certification Ceremony' hosted by Incheon Metropolitan City and organized by Incheon Technopark on the 12th, solidifying its position as a growing company in the bio-pharmaceutical development sector.
Founded in 2018, RudaCure has been dedicated to developing innovative drugs that directly and indirectly modulate the TRPV1 (Transient Receptor Potential Vanilloid 1) ion channel, offering new treatment options for patients suffering from sensory disorders such as dry eye disease and chronic pain.
RudaCure's core technology is a novel drug platform that directly and indirectly modulates the TRPV1 ion channel, which regulates pain, inflammation, and temperature sensation. TRPV1 is expressed in sensory nerves and plays a crucial role in pain signal transmission and inflammatory responses. By effectively modulating this channel, RudaCure is developing innovative drugs capable of treating various sensory disorders. The company's flagship pipeline, dry eye disease treatment 'RCI001,' utilizes a mechanism that suppresses inflammatory activation through TRPV1 downstream signal modulation. Unlike existing treatments, it demonstrates powerful anti-inflammatory and antioxidant effects, showing therapeutic results within 4 weeks along with confirmed increases in tear production. Notably, it has been recognized for overcoming major side effects associated with steroid-based treatments, including elevated intraocular pressure, hyperemia, hemorrhage, and burning sensation upon instillation.
RudaCure signed two technology transfer agreements with Hanlim Pharmaceutical totaling KRW 20 billion in 2021 and 2022, gaining recognition for RCI001's technical excellence. In July 2025, the company achieved FDA Phase 2 IND (Investigational New Drug) approval, with domestic Phase 2 clinical trials planned for 2026. The company is also expanding into the veterinary pharmaceutical market with a KRW 50 billion contract with a French global veterinary drug developer.
The chronic pain treatment 'RCI002' is a dual-target non-narcotic analgesic that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor). In preclinical studies, it demonstrated prolonged efficacy at concentrations 650 times lower than existing treatments with no side effects, and is applicable to various sensory disorders including neuropathic pain, chemotherapy-induced pain, and diabetic pain without the addiction risk of narcotic analgesics.
Behind RudaCure's selection as an outstanding company is not only its excellent technology but also its stable organizational culture. The company has fostered an environment where employees grow together based on its 3C core values: Creativity, Collaboration, and Challenge.
The company offers various financial incentives including stock options, performance bonuses, and long-service allowances, along with flexible work culture such as liberal use of annual leave and casual dress code. It also actively supports employee self-development through education expense subsidies and professional skill enhancement training. As a result, the company maintains a low turnover rate, and employees are moving toward the goal of innovative drug development as One Team, backed by high workplace satisfaction and pride.
RudaCure has consistently been recognized for its organizational excellence, being selected as a Talent-Nurturing SME, Outstanding Job Invention Compensation Company, and Work Innovation Excellence Company in 2022. In 2023, it was selected for the Ministry of Employment and Labor's Strong Small Enterprise program and the Ministry of SMEs and Startups' Startup Leap Package support program. In 2024, it was selected for the Baby Unicorn 200 Development Program, demonstrating its growth potential. The company has raised over KRW 16 billion in total investment through Series A (KRW 6 billion) and Series B (KRW 10 billion), strengthening its R&D capabilities. Through technology transfer agreements with Hanlim Pharmaceutical and a French veterinary pharmaceutical developer, the company has signed contracts totaling over KRW 70 billion, and is currently discussing technology transfer for pain treatment RCI002 with multiple overseas companies. Continuous revenue growth and technology transfer achievements further enhance the company's development potential.
CEO Yongho Kim of RudaCure is an expert who has conducted over 15 years of basic medical research on pain and sensory disorders as a professor at Gachon University College of Medicine. The company continues to secure globally competitive talent, including the recruitment of Research Director Jiyoon Shin to enhance drug development efficiency using AI.
CEO Kim stated, "This selection as an Incheon Outstanding Company is a recognition of RudaCure's R&D capabilities and innovative technology," adding, "Based on our proprietary TRPV1 modulation technology platform, we will provide more effective and safer treatment options for patients suffering from sensory disorders and grow into a globally competitive pharmaceutical development company."
RudaCure is targeting an IPO by 2027 in the mid-to-long term. To this end, the company is concentrating all its capabilities on generating R&D achievements through successful clinical trials and global technology transfers. Through its presence at Incheon Startup Park and its New York office in the US, the company is building a global cooperation network and laying the foundation for growth into a world-class pharmaceutical company.
With its headquarters in Songdo, Yeonsu-gu, Incheon and its research center in Gasan, Geumcheon-gu, Seoul, RudaCure contributes to local job creation and economic development while establishing itself as a socially responsible company through the adoption of eco-friendly drug manufacturing technology and sustainable management practices.
